{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=54&sponsor=AstraZeneca",
    "query": {
      "sponsor": "AstraZeneca",
      "page": 54
    },
    "page_size": 10
  },
  "pagination": {
    "page": 54,
    "page_size": 10,
    "total_count": 1904,
    "total_pages": 191,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=55&sponsor=AstraZeneca&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=53&sponsor=AstraZeneca&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-03T16:43:02.141Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00122070",
      "title": "Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Borderline Personality Disorder"
      ],
      "interventions": [
        {
          "name": "Quetiapine Fumarate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Medicine and Dentistry of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 15,
      "start_date": "2005-05",
      "completion_date": "2008-05",
      "has_results": false,
      "last_update_posted_date": "2008-06-10",
      "last_synced_at": "2026-11-03T16:43:02.141Z",
      "location_count": 1,
      "location_summary": "Cherry Hill, New Jersey",
      "locations": [
        {
          "city": "Cherry Hill",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00122070"
    },
    {
      "nct_id": "NCT00227305",
      "title": "Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia",
        "Bipolar I Disorder"
      ],
      "interventions": [
        {
          "name": "quetiapine fumarate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 381,
      "start_date": "2004-08",
      "completion_date": "2007-12",
      "has_results": true,
      "last_update_posted_date": "2013-01-08",
      "last_synced_at": "2026-11-03T16:43:02.141Z",
      "location_count": 31,
      "location_summary": "Dothan, Alabama • Scottsdale, Arizona • Cerritos, California + 28 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00227305"
    },
    {
      "nct_id": "NCT02637037",
      "title": "A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bioequivalence",
        "Fixed Dose Combination Tablets",
        "Healthy Male and Female Subjects"
      ],
      "interventions": [
        {
          "name": "dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon)",
          "type": "DRUG"
        },
        {
          "name": "dapagliflozin/metformin XR 5/500 mg reference drug (Humacao)",
          "type": "DRUG"
        },
        {
          "name": "dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)",
          "type": "DRUG"
        },
        {
          "name": "dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 80,
      "start_date": "2015-12-21",
      "completion_date": "2016-04-07",
      "has_results": true,
      "last_update_posted_date": "2018-03-13",
      "last_synced_at": "2026-11-03T16:43:02.141Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02637037"
    },
    {
      "nct_id": "NCT01703260",
      "title": "Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nonalcoholic Steatohapatitis"
      ],
      "interventions": [
        {
          "name": "Roflumilast",
          "type": "DRUG"
        },
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 20,
      "start_date": "2013-06",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2017-02-01",
      "last_synced_at": "2026-11-03T16:43:02.141Z",
      "location_count": 4,
      "location_summary": "Coronado, California • Annapolis, Maryland • Baltimore, Maryland",
      "locations": [
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "Annapolis",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01703260"
    },
    {
      "nct_id": "NCT02197247",
      "title": "Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Pharmacokinetic sampling - AZD9291",
          "type": "PROCEDURE"
        },
        {
          "name": "Rifampicin",
          "type": "DRUG"
        },
        {
          "name": "AZD9291 tablet dosing",
          "type": "DRUG"
        },
        {
          "name": "Pharmacokinetic sampling - rifampicin",
          "type": "PROCEDURE"
        },
        {
          "name": "Pharmacokinetic sampling - AZ5140 and AZ7550",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 41,
      "start_date": "2014-12-04",
      "completion_date": "2021-05-26",
      "has_results": true,
      "last_update_posted_date": "2021-07-12",
      "last_synced_at": "2026-11-03T16:43:02.141Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia • Detroit, Michigan",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02197247"
    },
    {
      "nct_id": "NCT03317158",
      "title": "Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Urothelial Carcinoma",
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Durvalumab (Cohort 1-3)",
          "type": "DRUG"
        },
        {
          "name": "External Beam Radiotherapy (EBRT)",
          "type": "RADIATION"
        },
        {
          "name": "Bacillus Calmette-Guérin (BCG)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Durvalumab (Cohort 4/5)",
          "type": "DRUG"
        },
        {
          "name": "To be determined",
          "type": "OTHER"
        },
        {
          "name": "Intravesical NAI (Cohorts 6-7)",
          "type": "DRUG"
        },
        {
          "name": "Subcutaneous NAI (Cohort 8)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Noah Hahn, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 186,
      "start_date": "2017-11-21",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-15",
      "last_synced_at": "2026-11-03T16:43:02.141Z",
      "location_count": 9,
      "location_summary": "Phoenix, Arizona • Indianapolis, Indiana • Iowa City, Iowa + 6 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03317158"
    },
    {
      "nct_id": "NCT00263276",
      "title": "A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 389,
      "start_date": "2005-12",
      "completion_date": "2007-02",
      "has_results": false,
      "last_update_posted_date": "2016-11-17",
      "last_synced_at": "2026-11-03T16:43:02.141Z",
      "location_count": 111,
      "location_summary": "Bayou La Batre, Alabama • Birmingham, Alabama • Huntsville, Alabama + 107 more",
      "locations": [
        {
          "city": "Bayou La Batre",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00263276"
    },
    {
      "nct_id": "NCT00489268",
      "title": "Micro-Layer Ablation of Barrett's Metaplasia- A Two-Phase, Multi-Center Trial - Extension of Follow-up to 5 Years",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Barrett Esophagus"
      ],
      "interventions": [
        {
          "name": "HALO Ablation System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Covidien, GI Solutions",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 102,
      "start_date": "2003-11",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2017-03-13",
      "last_synced_at": "2026-11-03T16:43:02.141Z",
      "location_count": 9,
      "location_summary": "Scottsdale, Arizona • Orange, California • Boston, Massachusetts + 6 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00489268"
    },
    {
      "nct_id": "NCT01972217",
      "title": "Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "Prednisone or prednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "MALE",
        "summary": "18 Years to 130 Years · Male only"
      },
      "enrollment_count": 158,
      "start_date": "2014-04-01",
      "completion_date": "2023-08-24",
      "has_results": true,
      "last_update_posted_date": "2023-11-14",
      "last_synced_at": "2026-11-03T16:43:02.141Z",
      "location_count": 2,
      "location_summary": "San Diego, California • Lake Success, New York",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Lake Success",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01972217"
    },
    {
      "nct_id": "NCT02058940",
      "title": "Intravenous Exenatide in Patients With Acute Brain Injury",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Brain Injuries"
      ],
      "interventions": [
        {
          "name": "Exenatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2015-08",
      "completion_date": "2017-08",
      "has_results": true,
      "last_update_posted_date": "2018-07-12",
      "last_synced_at": "2026-11-03T16:43:02.141Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02058940"
    }
  ]
}